Brought to you by 
Qiagen buys artus for cash and earn-outs
08 Jun 2005
Executive Summary
Qiagen NV (products and services for nucleic acid and protein separation, purification, and handling) is acquiring artus GMBH, a developer of PCR-based molecular diagnostics used in pathogen detection, genotyping, and pharmacogenomics. The company will pay about €17mm ($21.3mm) in cash, plus an additional $11.6mm in potential earn-outs.
Deal Industry
- In Vitro Diagnostics
-
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
-
Drug Discovery Tools
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Qiagen buys artus for cash and earn-outs
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice